Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma

Completed

Conditions studied: Liver Neoplasms

In brief

To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.

Key facts

Study ID

NCT02489838

Run by

Alan Katz

People needed

56

Starts

2012-02-03

Expected to finish

2019-08-07

Last updated by the study team

2020-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults ≥ 18 years with no upper limit.-Receiving Y-90 Therasphere liver directed therapy
• Pathology proven diagnosis of hepatocellular carcinoma, metastatic colon cancer or other metastatic diseases to be treated with SIRT (Y-90)
• surgical resection not feasible at time of initiation of pre-treatment workup
• > 6 months projected life span
• ECOG 0-2

You may not qualify if…

• previous radioembolization of one or more liver lobes or segments without available treatment planning and procedural documentation ie. at another facility prior to URMC Y-90 radioembolization.

Where it is running

• Radiation Oncology, University of Rochester, Medical Center — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.